Illustrations and figures are in italic. Tables are in bold.

abscesses, 290, 304
acacetazolamide, 265
achondroplasia, 170
acoustic impedance, 3–4
acoustic murmurs, “seagull cry”, 22
acoustic power, 5
acoustic shadowing, 10, 18–19, 20, 351
ADC see apparent diffusion coefficient
adhesion molecules, 328, 330
adventitial vasa vasorum, 35
age of patient, temporal window differences, 15
agenesis, 143, 154
air embolism, 210
agenesis, 143, 154
Alzheimer disease, 267, 288–90
American Heart Association (AHA) classifications, 328, 329
aneurysms
3D imaging, 231, 232, 237
3T magnetic resonance angiography (MRA), 190
arteriovenous malformation (AVM), 225
clinical vignette, 247–9
computed tomography angiography (CTA), 74, 76–7, 85, 86, 87–90, 91, 103, 213
contrast-enhanced magnetic resonance angiography (CE MRA), 182, 183, 188, 203
definition, 223
digital subtraction angiography (DSA), 87, 89, 210, 212, 213, 214, 231, 232, 237
dissecting, 224
Doppler ultrasound, 18
dynamic susceptibility contrast (DSC) MRI, 223–4
etiology, 87, 147, 154, 183
fusiform, 224
hemodynamics, 236
incidence, 149, 189
infectious, 224
intravenous (IV) C-arm FPD CT angiography, 241, 242
mortality rate, 183, 189
neck-to-dome ratio, 213
pediatric patients, 395, 400
phase contrast magnetic resonance angiography (PC MRA), 143, 164, 169–72
prevalence, 183
time-of-flight magnetic resonance angiography (TOF MRA), 133, 148–9, 182
types, 223
volume measurement, 231, 232
angiogenesis, 330–1
angiogenic switch, 284
angiography, conventional, 381–2, 384–5
angiography (PC MRA), 147
vasospasm, 27
time-of-flight magnetic resonance angiography
anteriormagnetic resonance angiography (PC MRA), 147
vasospasm, 27
velocity, 162
anteriormagnetic resonance angiography (PC MRA), 147
vasospasm, 27
time-of-flight magnetic resonance angiography
anteriortime-of-flight magnetic resonance angiography
anteriormagnetic resonance angiography (PC MRA), 147
vasospasm, 27
velocity, 162
arterial dissection
arterial spin labeling (ASL), 301
computed tomography angiography (CTA), 75, 115–17
contrast-enhanced magnetic resonance angiography (CE MRA), 180, 215, 217
time-of-flight magnetic resonance angiography (TOF MRA), 133, 150–1, 155
trauma, 100
ultrasound sonography, 41, 42
arteriovenous malformation (AVM)
3D imaging, 231, 235
3T magnetic resonance angiography (MRA), 190, 191
4D imaging, 202
4D imaging, 202
arterial spin labeling (ASL), 200
classification, 93
clinical vignette, 204
computed tomography angiography (CTA), 74–5, 78, 93–4, 97, 99, 103
computed tomography perfusion (CTP), 271
 arteriovenous fistula (AVF)
arteriovenous fistula (AVF)
arteriosclerotic disease
arteriovenous malformation (AVM) (cont’d)
contrast-enhanced magnetic resonance angiography (CE MRA), 202, 204
digital subtraction angiography (DSA), 212, 213, 214, 224–5, 231, 235, 236
hemodynamics, 236
incidence, 150
nidus size, 93, 202, 213
pediatric patients, 150, 395, 400
phase contrast magnetic resonance angiography (PC MRA), 164, 165, 171
time-of-flight magnetic resonance angiography (TOF MRA), 132, 150, 157
treatment plans, 150
ultrasound sonography, 41, 43
arteritis, 36–41
ASPECTS (Alberta Stroke Program Early CT Score), 263
aspirin, effect on digital subtraction angiography (DSA), 210
astrocytomas, 283–5
Asymptomatic Carotid Atherosclerosis Group (ACAS), 75, 112
atherosclerotic disease see also plaque; stenosis
cervical vascular ultrasound, 33, 34, 35
critical vignettes, 332–40
computed tomography angiography (CTA), 75, 79, 92–3, 111, 112–14
carbon dioxide as contrast material, 219
carbogen inhalation, 54
cerebral microembolic signals detection, 47
cerebral autoregulation, 55–6
cerebral circulation, 53
cerebral circulation, 53
color-coded digital subtraction angiography (DSA), 233–5, 236, 237
color-flow intravascular ultrasound sonography, 355, 366
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
computed tomography perfusion (CTP), 257–8, 260–3, 264
carotid arteries
carotid artery dissection
Carotid Consensus Panel criteria, 115–16
carotid plaque
artery wall thickness (CAWT), 317, 320
atherosclerotic disease see also plaque; stenosis
cerebral microembolic signals detection, 47
cerebral autoregulation, 55–6
cerebral circulation, 53
color-coded digital subtraction angiography (DSA), 233–5, 236, 237
color-flow intravascular ultrasound sonography, 355, 366
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
carotid arteries
carotid artery dissection
arterial spin labeling (ASL), 294, 303
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
carotid arteries
arterial spin labeling (ASL)
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
carotid arteries
arterial spin labeling (ASL)
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
carotid arteries
arterial spin labeling (ASL)
carotid aneurysms, 36, 37
peak systolic velocity (PSV), 37
plaque; stenosis, 55
carotid arteries
classification, 314, 317, 328, 328, 329
computed tomography angiography (CTA), 317–21
digital subtraction angiography (DSA), 312
imaging technique comparison, 313
motion studies, 35
neovascularization, 35
optical coherence tomography (OCT), 361, 362
pathogenesis, 309–12
as risk factor for stroke, 309
ultrasound sonography, 314–16, 317
carotid siphon
Doppler ultrasound, 15
plaque formation, 18
Carotid Stenosis Index (CSI), 113
carotid-cavernous fistulae (CCFs), computed
tomography angiography (CTA), 100
CASL (continuous arterial spin labeling), 294
cathepsin cystein proteases (CCPs), 330
cather angiography, 153, 155, 156, 157, 186, 209, 231
cather artifacts, 351
cather permeability, 84
cavernomas, 377, 378, 396, 398
cBFV see cerebral blood flow velocity
CCA/ICA PSV ratio, 21
CCPs (cathepsin cystein proteases), 330
CDU see cerebral duplex ultrasonography
CE MRA see contrast-enhanced magnetic resonance angiography
central nervous system
computed tomography angiography (CTA), 73
primary angiitis (PACNS), 227
vasculitis, 95–6, 384
cerebral autoregulation, 55–6
cerebral blood flow velocity (cBFV), 55, 57
cerebral circulatory arrest, transcranial Doppler (TCD) ultrasound, 53–4
cerebral hemodynamic monitoring, 33, 49–54
 cerebrospinal fluid (CSF), 376–7
cerebrovascular occlusive disease, 303–5
cervical artery dissection
computed tomography angiography (CTA), 100
ultrasound sonography, 25–6
cervical duplex ultrasonography (CDU), 14
cervical vascular ultrasound, 33, 34–41
cesium iodide scintillator screens, 229
CFO see computational fluid dynamics
chemical shift artifacts, 188
chickenpox, 383
children see pediatric patients
cholesterol, 309
cine imaging, 139, 141, 143, 166–69, 259
circle of Willis
magnetic resonance angiography (MRA), 187
time-of-flight magnetic resonance angiography (TOF MRA), 133, 147
transcranial Doppler (TCD) ultrasound, 41
transcranial Doppler ultrasound, 18
clinical trials
Asymptomatic Carotid Atherosclerosis Group (ACAS), 75, 112
Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS), 47
Clopidogrel plus Aspirin versus Aspirin Alone for Reducing Embolization in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR), 47
European Carotid Surgery Trial (ECTS), 24, 112–13, 221
North American Symptomatic Carotid Endarterectomy Trial (NASCET), 24, 75, 112–13, 149, 221, 309
Prolyse in Acute Cerebral Thromboembolism (PROACT), 222
Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS), 92
STOPStroke study, 97
Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA), 45
Stroke Prevention Trial in Sickle Cell (STOP), 47
Veteran’s Administration Symptomatic Stenosis Trial (VASSIT), 180
Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial, 47
Clopidogrel plus Aspirin versus Aspirin Alone for Reducing Embolization in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR) trial, 47
Cognard classification, 96
color Doppler imaging, 9–10, 11, 12, 18, 19, 22
cerebrovascular occlusive disease, 303–5
cerebral artery dissection
computed tomography angiography (CTA), 100
cerebral hemodynamic monitoring, 33, 49–54
cerebrospinal fluid (CSF), 376–7
cerebral blood flow velocity (cBFV), 55, 57
cerebral circulatory arrest, transcranial Doppler (TCD) ultrasound, 53–4
cerebral hemodynamic monitoring, 33, 49–54
cerebral posterior artery (P2), Doppler ultrasound, 15, 17
cerebral sinovenous thrombosis (CSVt), pediatric patients, 389, 390–5, 399–400
cerebral sinus thrombosis, 57, 83
cerebral vasconstriction syndromes, 46, 49
cerebral vasoreactivity studies, 33–4, 54–8, 61
 cerebrospinal fluid (CSF), 376–7
computed tomography sonography (CTV), 101–2
contrast-enhanced magnetic resonance angiography (CE MRA), 202–3
cord sign, 102
empty delta sign, 102
magnetic resonance imaging (MRI), 102
risk factors, 153
time-of-flight magnetic resonance angiography (TOF MRA), 153
computed tomography angiography (CTA), 114–15, 318
intracranial vascular ultrasound sonography, 349, 350
imaging technique comparison, 314
intravascular ultrasound sonography, 349, 350
physiology, 14
stenosis, 22
Takayasu disease, 40
time-of-flight magnetic resonance angiography (TOF MRA), 154
table speed, 70
time-of-flight magnetic resonance angiography (TOF MRA), 154
table speed, 70
transcranial Doppler ultrasound, 18
clinical trials
Asymptomatic Carotid Atherosclerosis Group (ACAS), 75, 112
Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS), 47
Clopidogrel plus Aspirin versus Aspirin Alone for Reducing Embolization in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR), 47
European Carotid Surgery Trial (ECTS), 24, 112–13, 221
North American Symptomatic Carotid Endarterectomy Trial (NASCET), 24, 75, 112–13, 149, 221, 309
Prolyse in Acute Cerebral Thromboembolism (PROACT), 222
Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS), 92
STOPStroke study, 97
Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA), 45
Stroke Prevention Trial in Sickle Cell (STOP), 47
Veteran’s Administration Symptomatic Stenosis Trial (VASSIT), 180
Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial, 47
Clopidogrel plus Aspirin versus Aspirin Alone for Reducing Embolization in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR) trial, 47
Cognard classification, 96
color Doppler imaging, 9–10, 11, 12, 18, 19, 22
cerebrovascular occlusive disease, 303–5
cerebral artery dissection
computed tomography angiography (CTA), 100
cerebral hemodynamic monitoring, 33, 49–54
cerebrospinal fluid (CSF), 376–7
computed tomography angiography (CTA), 100
cerebral blood flow velocity (cBFV), 55, 57
computed tomography venography (CTV)
apPLICATIONS, 83, 101–2
artefact causes, 100–1
compared to MRI, 102
extracranial protocols, 83
imaging protocols, 100
intracranial protocols, 83
pitfalls, 100–1
risks, 83
source images (SIs), 100
cone artifacts, 72
cone beam C-arm imaging, 230
continuous arterial spin labeling (CASL), 294
contrast-enhanced magnetic resonance
angiography (CE MRA)
4D, 194–204
advantages, 133, 197, 198, 322
applications, 179–83, 201–3, 322, 330
artefact causes, 133, 178, 200
clinical vignette, 183–4, 204
compared to CTA, 180
compared to Doppler ultrasound, 180
compared to DSA, 202, 212, 213–15
compared to PC MRA, 167
compared to TOF MRA, 153, 155, 176, 177, 178, 180, 182, 183, 384
costs, 178
development of, 127
imaging protocols, 176–8, 200–1, 202, 203
limitations, 133, 176, 178, 180, 197, 198, 200, 212
pediatric patients, 384
pitfalls, 178, 200
principles of 4D, 194–200
time-resolved, 178, 179
contrast enhancement
attenuation, 258
bolus-tracking, 83, 84, 86, 178, 276
computed tomography angiography (CTA), 70, 73–4, 80–1, 83, 84, 110
patient weight, 73
phase contrast magnetic resonance
angiography (PC MRA), 164
plaque molecular imaging, 330–1
time-of-flight magnetic resonance angiography
(TOF MRA), 131
ultrasmall paramagnetic iron oxide nanoparticles (USPIOs), 330
ultrasound, 35, 36, 314–16, 317, 334
ultrasound sonography, 334
contrast-induced nephropathy, 70, 127, 260, 317
contrast leak effect, 276
critical closing pressure (CCP), 55
critical flow velocity (Vc), 127–8, 134
CTA see computed tomography angiography
CTV see computed tomography venography
decibels (dB), 3
deconvolution techniques, 258
DFT (driven-equilibrium Fourier transform), 322
dental amalgam, 111, 117
Denver screening for BCVI, 100
depth-gain compensation, 6
destruction kinetics, 59
detector quantum efficiency (DQE), 230
Diamox test, 55
diffuse reflectors, 4, 5
diffusion tensor imaging (DTI), 381
diffusion-weighted magnetic resonance imaging
(DWI), 69, 75, 257, 260, 277–9, 290, 302, 377, 398–9
digital roadmaps, 232, 234–5
digital subtraction angiography (DSA)
3D, 229, 230, 231, 232
3D imaging, 246
advantages, 212, 221
applications, 212–19, 312
artefact causes, 210, 231, 237, 238
C-arm imaging, 230
clinical vignette, 219, 247–9
color-coded, 218–19, 233–5
contrast-enhanced magnetic resonance imaging
compared to TOF MRA, 149, 150
computational fluid dynamics (CFD), 235–7
costs, 92, 219
detector quantum efficiency (DQE), 230
development of, 209, 229
digital image processing system, 209
digital roadmaps, 232, 234–5
dual-volume imaging, 232, 233, 234
de edge enhancement, 209
flat-panel detectors (FPDs), 229–30, 231, 232
fusion imaging, 233
hemodynamics, 233–5, 236
imaging protocols, 210–12, 218
imaging sequences, 218
limitations, 312
mask, 209, 210, 232
morbidity rate, 212
mortality rate, 212
pitfalls, 210
pixel shifting, 210
principles, 209–10
radiation exposure, 210
research applications, 218–19
rotational, 219, 229, 231, 246
signal-to-noise ratio (SNR), 209
diplol, temporal window differences, 15
DIR (double-inversion recovery), 322
dissecting aneurysms, 224
Doppler ultrasound
advantages, 374
applications, 313–16
artefact causes, 10–11
cardiac cycle, 9
cerebral hemodynamic monitoring, 33, 49–54
cerebral vasoreactivity studies, 33–4, 54–8, 61
cervical vascular ultrasound, 33, 34–41
clinical vignette, 29–31, 60–1, 332–4
compared to CE MRA, 180
compared to PC MRA, 168, 170
continuous-wave, 6, 8
degree of insonation, 5, 6, 7
display, 7–10
Doppler angle, 11, 13
duplex, 7, 11
echo color Doppler (US ECD), 313–14
extracranial vascular applications, 18–27
flow parameters, 13
flow resistance, 12–13
flow types, 11–12
frequency shift, 6, 7, 8, 10, 11
gain, 11
imaging protocols, 14–18
indices, 9, 11, 13
instrumentation, 6–7
intracranial vascular applications, 27–8
intracranial vasculopathies, 33, 41–7
limitations, 6, 18–19, 314
microembolic signals (MES) detection, 33, 47, 51
Nyquist limit, 11
patient position, 14, 15
pediatric patients, 384, 387–8
power motion–mode (PMD), 49, 52
pulse repetition frequency (PRF), 11
pulsed-wave, 7, 8, 11
transcranial (TCD), 15–18, 33, 41–2, 47, 49–54, 56–7, 387–8
double-exposure misregistration artifact, 132
double-inversion recovery (DIR), 322
Down syndrome, computed tomography
angiography (CTA), 98
driven-equilibrium Fourier transform (DEFT), 322
DSACE see digital subtraction angiography
DSCE MRI see dynamic susceptibility contrast-enhanced magnetic resonance imaging
dual-energy computed tomography angiography
(DECTA), 321
dual-volume 3D digital subtraction angiography, 232, 233, 234
duplex Doppler ultrasound
artefact causes, 11
blood flow, 7
cerebral hemodynamics, 18, 20
occlusions, 23
plaque composition, 20, 21, 22
dural arteriovenous fistula (dAVF) see
arteriovenous fistula
dural fistula see arteriovenous fistula
dural sinus thrombosis, 167
dynamic susceptibility contrast (DSC) MRI,
leptomeningeal collaterals, 222
dynamic susceptibility contrast-enhanced
magnetic resonance imaging (DSCE MRI)
advantages, 277, 290
Index

applications, 277–91
artifact causes, 276
ingaging protocols, 276–7
pitfalls, 276
principles, 275–6
research developments, 291–2
ear surgery, aberrant internal carotid artery, 146
echo-planar imaging (EPI), 138, 296
echo ranging, 3, 4
echo times (TEs)
contrast-enhanced magnetic resonance angiography (CE MRA), 177
phase contrast magnetic resonance angiography (PC MRA), 140–1
Eddy current effects, 163
demyelination, 36
euritis, 309, 400
endo-diastolic velocity
cephalalgia, 21, 22
endarterectomy
carotid aneurysms, 36
carotid stenosis, 24, 112, 118, 221, 222, 312
Doppler ultrasound, 26–7, 49
intradural stenosis, 21, 22
endarterectomy
endocardial dysfunction, 328–30
epilepsy, 287–8, 304
European Carotid Surgery Trial (ECS), 24, 35
European Carotid Surgery Trial (ECTS), 24, 25
external carotid artery (ECA)
atherosclerotic disease, 18
computed tomography angiography (CTA), 95
digital subtraction angiography (DSA), 233
dural stenosis, 41
physiology, 14
stenosis, 41
ultrasound sonography, 12, 14, 23, 41
velocity, 162
external elastic membrane area (EEM), 349, 351
extracranial carotid lesions, Doppler ultrasound, 28
extracranial vascular disease (EVD), 111–12
fast low-angle shot (FLASH) sequence, 177
fast spoiled gradient recalled (FSPGR) sequence, 177
fat saturation, 129
FCA (focal cerebral arteriopathy of childhood), 383, 390
Feldkamp algorithm, 230, 232
fibrin, 331
fibrocalcific plaques, 311
fibromuscular dysplasia, craniovascular artery dissection, 25
fibromuscular dysplasia (FMD)
computed tomography angiography (CTA), 117
digital subtraction angiography (DSA), 213, 216
incidence, 117
ultrasound sonography, 35–6
fibrous cap atheroma, 310, 325
first-pass pharmacokinetic modeling (FPPM), 276
fistulae, 12
FLASH (fast low-angle shot) sequence, 177
flat-panel detectors (FPDs), digital subtraction angiography (DSA), 229–30, 231, 232
flip angles, 127, 128, 131, 188
flow-compensated gradient waveforms, 130, 138
flow-encoding gradient, 137, 138
flow-related enhancement see inflow enhancement
flow-sensitive dephasing (FSD), 144
fluid-attenuated inversion recovery (FLAIR)
sequence, 284, 288, 377, 385, 393
18fluorodeoxyglucose (FDG), 330
fluoroscopy, dose reduction, 246, 247
fluorodeoxyglucose positron emission tomography (FDG-PET), 221, 330
foam cells, 309, 328, 330
focal cerebral arteriopathy of childhood (FCA), 383, 390
fornamen magnum window see transforaminal window
Fourier transform, 8
FPPM (first-pass pharmacokinetic modeling), 276
Framingham Heart Study, 112
frontal window, 18
FSPGR (fast spoiled gradient recalled) sequence, 177
fusiform aneurysms, 224
globulin, 127, 178, 198, 297, 330, 331
see also contrast enhancement
gain, ultrasound, 11
gender, temporal window differences, 15
generalized autocalibrating partially parallel acquisition (GRAPPA), 195
giant cell arteritis (GCA), B-mode echotomography, 40–1
gradient echo (GRE) sequence, 128–9, 130, 138
GRAPPA (generalized autocalibrating partially parallel acquisition), 195
GRE (gradient echo) sequence, 129, 130, 138
groin hematomas, digital subtraction angiography (DSA), 211, 212
Hagen–Poiseuille law, 11
halo sign, 40
head injury see also trauma
autoregulatory index (ARI), 55
computed tomography angiography (CTA), 98–100, 117
computed tomography perfusion (CTP), 269
Doppler ultrasound, 27–8
time-of-flight magnetic resonance angiography (TOF MRA), 155
headaches
arteriovenous fistula (AVF), 212
computed tomography angiography (CTA), 74
thunderclap, 46
hematomas, digital subtraction angiography (DSA), 211, 212
hemodynamics see also blood flow; computed tomography perfusion
color-coded digital subtraction angiography (DSA), 233–5, 236, 237
computational fluid dynamics (CFD), 235–7
dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSCE MRI), 277
Hagen–Poiseuille law, 11
Law of Poiseuille, 167
magnetic resonance angiography (MRA), 194, 201, 203–4
mean transit time (MTT), 237, 257–8, 260–3, 264, 271, 275–6, 277
Navier–Stokes equation, 167
occlusions, 277
perfusion imaging, 257
phase contrast magnetic resonance angiography (PC MRA), 167–70, 171, 198
pulsatility index (PI), 168–9
stenosis, 19–23
time to decay (TTD), 237
time to peak (TTP), 237, 258, 263, 276, 385
ultrasound sonography, 15, 18, 19–25, 33
hemorrhagic stroke, 377, 395–6, 400
hepatic, effect on digital subtraction angiography (DSA), 210, 212
herpes encephalitis, 304
high-density lipoprotein (HDL), 309
HOP-MRA technique, 134
Hounsfield unit
seen also beam-hardening artifacts
hybrid of opposite-contrast (HOP)-MRA technique, 134
hybrid rooms, 246
hydrocephaly, 143, 170, 237, 267, 268, 400
hypercapnia, 303
hyperemia, 46, 48
hyperperfusion, 263, 269, 282, 295, 298, 299, 303, 305
hypervolemia, 27
hypoglycemia, 267
hypoplasia, 147, 154
hypoxia, 267
ICA-CCA ratio
restenosis criteria, 27
stenosis, 24
ICA-3CA mean velocity (ICA-3CA MV) ratio, 21
ICH see intracerebral hemorrhage
IDEAL technique (iterative decomposition of water and fat using echo asymmetry and least-squares estimation), 130
pediatric patients see also moyamoya disease
aneurysms, 395, 400
arterial spin labeling (ASL), 294, 295, 296
arteriopathies, 383–4
arteriovenous malformation (AVM), 150, 395, 400
blood flow, 377
cardiac disease, 385–7
cerebral sinovenous thrombosis (CSVT), 389, 390–5, 399–400
clinical vignette, 401
computed tomography angiography (CTA), 374–7, 378, 396
computed tomography perfusion (CTP), 376–7
conventional angiography, 381–2, 384–5
cranial ultrasound, 373–4, 387–8, 398, 400
cranio-cervical artery dissection, 25, 384–5
diffusion tensor imaging, 381
digital subtraction angiography (DSA), 211
doppler ultrasound, 374, 384, 387–8
local cerebral arteriopathy of childhood (FCA), 390
gene tic diseases, 390
hemorrhagic stroke, 377, 395–6, 400
infections, 390
ischemic strokes, 379, 380–1, 382–3, 384, 385, 397–9
magnetic resonance angiography (MRA), 379–80, 387–8
magnetic resonance imaging (MRI), 377–9, 386, 388, 393, 396, 398, 399
magnetic resonance perfusion, 380–1
maxillofacial vascular pathology, 98
metabolic diseases, 390
perinatal stroke, 375, 376, 396
physiologic pediatric brain hyperperfusion, 295, 296, 305
radiation exposure, 245, 294, 375–6
sickle cell disease, 46–7, 374, 377, 387–90, 391, 401
signal-to-noise ratio (SNR), 380
subarachnoid hemorrhage (SAH), 389, 395
thrombophilias, 390
time-of-flight magnetic resonance angiography (TOF MRA), 393
varicella zoster vasculopathy, 383, 384
venous thrombosis, 213
perfusion, 257, 275, 380
perfusion C-arm computed tomography, 243
perfusion-weighted magnetic resonance imaging (PWI), 257, 271, 275, 294
perimesencephalic subarachnoid hemorrhage, 101
perinatal stroke, 396
permeability surface–area product (PS), 269, 271
persistent carotid-basilar anastomosis, 147
persistent stapedial artery, 146–7
phase contrast magnetic resonance angiography (PC MRA)
4D, 169–70, 198
advantages, 163–4, 168–9, 199
applications, 143–4, 164–69
artifact causes, 138, 141, 162–3, 169
color-coded images, 142
compared to CE MRA, 166
compared to Doppler ultrasound, 168–69
compared to TOF MRA, 155, 161, 163, 164, 166, 198
development of, 127
grey-value coding, 139
imaging protocols, 139–43, 161–2, 166
limitations, 127, 163, 165–66, 169, 198
principles, 137–9, 186
phase shift errors, 141
phase velocity mapping, 139, 166
PI see pulsatility index
pixel shifting, 210
plaque see also atherosclerotic disease
angiogenesis, 330–1
angioplasty, 364–6, 367
B-mode echotomography, 18
calcification, 114, 155, 311, 314, 315, 320, 321, 328, 353
carotid artery wall thickness (CAWT), 317, 320
classification, 314, 317, 318, 328, 328, 329
clinical vignette, 368–9
clinical vignettes, 332–40
composition, 18, 155
computed tomography angiography (CTA), 75, 87, 114, 317–21
contrast-enhanced magnetic resonance angiography (CE MRA), 189
coronary, 318, 328
cross-sectional imaging, 221
digital subtraction angiography (DSA), 221, 312
echogenicity, 314
erosion, 311
formation sites, 18
hemorrhage, 324–5, 327, 329
high resolution MRI, 322–4, 328, 330
imaging technique comparison, 313
intravascular ultrasound sonography, 331, 349–51, 353–5, 356, 357, 358, 363
molecular imaging, 328–30
near-infrared spectroscopy (NIRS), 331
optical coherence tomography (OCT), 331, 361, 362, 363, 367
pathogenesis, 309–12, 328–30
posimionemission tomography (PET), 330
as risk factor for stroke, 309
rupture, 311, 312, 325, 353–4
thermography, 331
time-of-flight magnetic resonance angiography (TOF MRA), 133, 155, 322, 323, 324–5, 328
triplex Doppler ultrasound, 23
ulceration, 314, 316, 317–20, 318, 325, 335–6, 354
ultrasound sonography, 314–16, 317, 331
Virtual Histology™ (VH), 356, 357, 358–60
pontine emission tomography (PET), 221, 257, 267, 303, 330
posterior cerebral artery (PCA)
collateralization, 45
fetal origin, 147
vasospasm, 27
velocity, 162
posterior communicating artery, 15
posterior reversible leukoencephalopathy, 46
postvaricella arteriopathy, 383, 384
Poucelot index see resistivity index
power motion–mode Doppler (PMD), 49, 52
PRF see pulse repetition frequency
primary angitis of the central nervous system (PACNS), 227
Prolyse in Acute Cerebral Thromboembolism (PROACT) studies, 222
propagation velocity, ultrasound, 3, 5, 6
prospective triggering, 139
prosokinease, 222
proximal subclavian artery, 24–5
pseudoaneurysm, 117, 155, 180
pseudocontinuous arterial spin labeling (PCASL), 294
pseudostenosis artifact, 231
PSV see peak systolic velocity
pulsatile tinnitus, 41, 42, 95, 150, 212
pulsatility index (PI), 13, 22, 53, 168–9
pulse repetition frequency (PRF), 11
pulsed arterial spin labeling (PASL), 294
quiescent interval single-shot (QISS) technique, 134
radiation exposure
computed tomography angiography (CTA), 70, 103, 317
digital subtraction angiography (DSA), 210
dose reduction, 243–6, 247, 317, 375–6
FDA maximum limits, 246
pediatric patients, 375–6
radiation necrosis, 285, 286
real-time 3D ultrasound (RT3D), 57–8
real-time imaging, 246
reflection, ultrasound, 3–4, 4–6, 5
refraction, 5, 6
renal patients
arterial spin labeling (ASL), 294
computed tomography angiography (CTA), 317
magnetic resonance angiography (MRA), 155
time-of-flight magnetic resonance angiography (TOF MRA), 146
reperfusion therapy, 49, 303
repitition times (TRs)
contrast-enhanced magnetic resonance angiography (CE MRA), 177
time-of-flight magnetic resonance angiography (TOF MRA), 127, 128
resistance-area product (RAP), 55
resistivity index (RI), 13, 41
respiratory triggering, 132
restenosis
computed tomography angiography (CTA), 117
criteria, 27
Doppler ultrasound, 26–7, 117, 118
intravascular ultrasound sonography, 354–5
retrospective gating, 139
Reynolds number (Re), 11
RI see resistivity index
right-to-left shunts (RLS), 47, 51
ring-down artifacts, 351
saturation gap, 129
"seagull cry", 22
seizures
arterial spin labeling (ASL), 304, 305
clinical vignette, 219
computed tomography perfusion (CTP), 269
dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSCE MRI), 287–8
epilepsy, 287–8
SENSe (sensitivity encoding), 195
servo-controlled finger photoplethysmography, 55
shaded surface display (SSD), 84, 85
shoulder artifacts, 72
shunts arteriovenous fistula (AVF), 150
blood flow, 12
normal pressure hydrocephalus (NPH), 267, 268
pulsatile tinnitus, 41
right-to-left (RLS), 47, 51
time-resolved MRA, 203
ultrasound sonography, 12, 41
sickle cell disease clinical vignette, 401
computed tomography angiography (CTA), 377
digital subtraction angiography (DSA), 213, 226
pediatric patients, 46–7, 374, 377, 387–90, 391, 401
ultrasound sonography, 46–7
signal-to-noise ratio (SNR) 1.5T compared to 3T, 187
arterial spin labeling (ASL), 303–5
carotid artery dissection, 25
CCA:ICA PSV ratio, 21
clinical vignette, 183–4, 368–9
computed tomography angiography (CTA), 75, 79, 110, 111, 113, 114, 118–20, 317, 321
contrast-enhanced magnetic resonance angiography (CE MRA), 180, 189, 199
diagnosis criteria, 46
diagnosis guidelines, 112
differentiation from occlusions, 113
digital subtraction angiography (DSA), 113, 114, 189, 212, 213–15, 216, 219, 221–2, 312
Doppler ultrasound, 9, 11, 12, 13, 15, 18–23, 27, 28, 41, 45, 113, 114
dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSCE MRI), 279–80, 283
echo colour Doppler (US ECD), 313–14, 314, 316
end-diastolic velocity, 21, 22, 24
etiology, 25
grade calculation, 19
grades, 24, 25, 45, 113, 149
hemodynamics, 19–23
ICA:CCA ratio, 24
ICA:ICA mean velocity (ICA:ICA MV) ratio, 21 incidence, 112
ischemic stroke, 24, 221
magnetic resonance angiography (MRA), 113, 114, 199
microembolic signals detection, 47
moyamoya disease, 46
peak systolic velocity (PSV), 21, 22, 24, 45
phased contrast magnetic resonance angiography (PC MRA), 143, 164, 170, 199
pseudostenosis artifact, 231
pulsatile tinnitus, 41
time-of-flight magnetic resonance angiography (TOF MRA), 130, 133, 149, 152, 154, 199, 321–2, 328
time-resolved MRA, 203
ultrasound contrast agents (UCAs), 59
water excitation false positives, 130
Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, 92
stents C-arm flat panel detector-based cone beam computed tomography (FPDCT), 237–8, 242, 247–9
clinical vignette, 368–9
computed tomography angiography (CTA), 75, 86, 88, 92–3, 117
contrast-enhanced magnetic resonance angiography (CE MRA), 203
Doppler ultrasound, 26–7, 49
intravascular ultrasound sonography, 351, 353, 354–5
intravenous (IV) C-arm FPD CT angiography, 241
optical coherence tomography (OCT), 363, 365
time-of-flight magnetic resonance angiography (TOF MRA), 155
STOPStroke study, 97
string of beads, 151, 155
stroke see also ischemic strokes arterial spin labeling (ASL), 300, 303–5
carotid artery wall thickness (CAWT), 320
cerebral blood flow (CBF), 260–3, 264, 277, 303
cerebral blood volume (CBV), 260–3, 264, 277
clinical vignette, 272–3, 332–3
computed tomography angiography (CTA), 75, 80, 96–7, 103, 105, 114–15
computed tomography perfusion (CTP), 260–3, 264–5, 271
cranio-cervical artery dissection, 25–6
death rates, 18
digital subtraction angiography (DSA), 80, 213, 215, 216
dissections, 35
Doppler ultrasound, 15, 18, 25–6, 45, 49, 52
dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSCE MRI), 277–9
etiology, 18, 25, 111–12, 373, 382, 386
incidence rate, 213, 373
intima-media thickness (IMT), 18
morbidity, 112
mortality rate, 154, 309
parietal thrombi, 36
pediatric patients, 373, 379, 380–1, 382–3, 384, 385, 386, 395–400
perfusion C-arm computed tomography, 243
perfusion magnetic resonance imaging (MRI), 294
phase contrast magnetic resonance angiography (PC MRA), 164, 170
recurrent stroke prevention, 115
reperfusion, 303
risk factors, 18, 24, 149, 212, 309, 320
Thrombolysis in Brain Ischemia (TIBI) classification, 45, 47
treatment plans, 260
types, 18
young adults, 35
Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial, 45

Index
gain, 11
history, 3
imaging protocols, 14–18
instrumentation, 6–7
Nyquist limit, 11
patient position, 14, 15
pediatric patients, 373–4, 398, 400
penetration efficiency, 5–6
principles, 3–6
propagation velocity, 3, 5, 6
pulse repetition frequency (PRF), 11
pulsed-wave, 7, 8, 11
radiofrequency (RF) data technology, 34
real-time 3D (RT3D), 57–8
reflection interfaces, 4–6
refraction, 5, 6
USPIOs (ultrasmall paramagnetic iron oxide nanoparticles), 330
varicella zoster vasculopathy, 383, 384
vascular dementia, 267
vascular endothelial growth factor (VEGF), 267–9, 330
vasculitis
computed tomography angiography (CTA), 95–6
digital subtraction angiography (DSA), 96, 213, 215–16, 217
etiology, 96, 151
pediatric patients, 381
symptoms, 151
time-of-flight magnetic resonance angiography (TOF MRA), 115
time of flight magnetic resonance angiography (TOF MRA), 131
ultrasound sonography, 15, 27, 45–6, 48, 92
vein of Galen
bulbous, 147–8
pediatric patients, 400
velocity see blood flow
velocity aliasing, 140, 162–3
velocity-encoding gradients, 137
velocity mapping, 139, 166
velocity-selective arterial spin labeling (VS-ASL), 294–5
VENC (velocity-encoded) parameter, 137, 139–40, 161–3, 165, 166, 198, 200
venetian blind artifact, 131–2
venous diseases, 57
venous infarcts, 291
venous system physiology, 101
venous thrombosis
computed tomography angiography (CTA), 97
digital subtraction angiography (DSA), 213, 216–18
time-of-flight magnetic resonance angiography (TOF MRA), 133
vertebral artery dissection
computed tomography angiography (CTA), 115, 116–7
contrast-enhanced magnetic resonance angiography (CE MRA), 180, 181
etiology, 25, 115, 180
time-of-flight magnetic resonance angiography (TOF MRA), 133
ultrasound sonography, 25, 35, 37
vertebral artery (VA)
averiovascular malformation (AVM), 150
vertebrobasilar system, 18
vessel area, 349, 351
vessel scouts, 141, 144
Veteran’s Administration Symptomatic Stenosis Trial (VASST), 180
Virtual Histology™ (VH) intravascular ultrasound, 356, 377, 358–60
volume rendering (VRT), 70, 78, 84, 85–6, 87, 88, 91, 111
VS-ASL (velocity-selective arterial spin labeling), 294–5
wall filters, ultrasound, 11
Wallenberg syndrome, 278
wash-in see infl ow enhancement
wash-out effect, 129
water excitation, 129–30
white cap artifacts, 351
Williams syndrome, 381
women
fibromuscular dysplasia (FMD), 117
postpartum venous thrombosis, 213
tests before digital subtraction angiography (DSA), 211
xenon-enhanced computed tomography (XeCT), 257, 267
young adults see also moyamoya disease
arteriovenous malformation (AVM), 150
craniovertebral junction (CVJ), 25
dissections, 35, 37–8, 115
fibromuscular dysplasia (FMD), 117